ClinicalTrials.gg
Status unknownNCT04298320Updated Mar 16, 2020

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC(SHR-1210-AIN457)

A Phase 1/2 interventional study of SHR-1210 and AIN 457 in Colorectal Cancer, sponsored by Yanqiao Zhang. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-16.

Sponsored by Yanqiao Zhang · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing camrelizumab in Colorectal Neoplasms — 6 open to participants now, 6 under way, none of them phase 3. camrelizumab · Colorectal Neoplasms.

Planned enrollment
8th of 17
40 · median 37
Started
2020
with 2 others
Phase 1/2
4 of 17
none open now
Registered
5th of 17
by date

Among the 17 studies testing camrelizumab in Colorectal Neoplasms, this one is the 8th largest by planned enrollment, is one of 3 that started in 2020, is one of 4 in phase 1/2, and was the 5th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 17 studies testing camrelizumab in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed second-line and above treatment.

The main purpose of this study is to evaluate the safety, tolerability and RD of SHR-1210 combination with AIN457 as a treatment of MSS CRC.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in this study and sign ;

    1. Men or women aged 18-75 years;
    2. Patients with advanced colorectal cancer who failed to receive or more standard treatment confirmed by pathology A)At least one that meets the v1.1 criteria; B)Microsatellite stability (MSS) required;
    3. score was 0 or 1;
    4. Have a of at least 12 weeks;
    5. The functions of vital organs meet the following requirements:

      A) Sufficient bone marrow reserve: neutrophil absolute count ≥ 1.5x109/l, ≥ 90x109 / L, ≥ 9 g / dl; B) Liver: plasma albumin ≥ 2.8g/dl; ≤ 1.5 times of value (ULN); and AST ≤ 2.5uln, if there is liver , ALT and AST ≤ 5xuln; C) Kidney: serum creatinine ≤ 1.5 times ULN; D) Heart: (LVEF) ≥ 50%; E) Coagulation: (PT) \< 1.5 times ULN, INR ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN; F) TSH ≤ ULN (if abnormal, FT3 and FT4 levels should be examined at the same time, if FT3 and FT4 levels are normal, they can be included in the group;

    6. Female Subjects of must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of for the course of the study through 3 months after the last dose of study treatment;
    7. Patients can provide more than 8 pathological sections of previous and / or fresh tissue lesions;
    8. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visit and research, understand the research procedures and have signed the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Those who have received anti-IL-17 or IL-23 drug treatment;
  2. Have received antibody treatment or other immunotherapy for PD-1/PD-L1;
  3. Those who have received chemotherapy, molecular targeted drugs and anti-tumor drugs of traditional Chinese medicine within one month after the first use of the research drug;
  4. The adverse reactions (except hair loss) caused by previous treatment did not recover to ≤ level 1;
  5. Those who have received radiotherapy and interventional treatment within one month after the first use of the study drug;
  6. Those who have received major surgery or active ulcer or incomplete wound healing within one month after the first use of the study drug (excluding central vein catheterization, tumor tissue or nasogastric tube catheterization);
  7. Those who received within one month after the first use of the study drug or expected to receive live attenuated vaccine treatment during the study period;
  8. Those who are expected to undergo elective surgery during the study period;
  9. Those who received transfusion of blood products and injection of hematopoietic colony stimulating growth factor (such as G-CSF, GMCSF, M-CSF) within 14 days after the first use of the study drug;
  10. Participants in another intervention clinical trial within one month after the first use of the study drug;
  11. Within 5 years after the first use of the study drug or at the same time with other malignant tumors (except for cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer);
  12. Patients with active disease, or history of immunodeficiency and autoimmune disease, or disease history or syndrome requiring drug treatment; (such as the following, but not limited to: asthma, idiopathic pulmonary fibrosis, bronchiolitis obliterans, colitis, drug pneumonia, idiopathic or interstitial pneumonia, autoimmune hepatitis, pituitary gland Inflammation, vasculitis, nephritis, uveitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism; patients with asthma in childhood have been completely relieved, and can be included in adults without any intervention, but asthma patients who need medical intervention with bronchodilator cannot be included);
  13. Need systemic hormone treatment;
  14. Intestinal obstruction or fistula occurred within 3 months after the first use of the study drug;
  15. Those who have ever had serious reaction (defined as: the patients can't be relieved quickly after symptomatic treatment and / or infusion treatment; relapse after taking effect; leave the sequelae requiring hospitalization treatment); those who have allergic reaction to latex products;
  16. People with tuberculosis (except old tuberculosis);
  17. People infected with or or ;
  18. There is active infection within 2 weeks after the first use of the study drug, or there is a history of persistent infection, chronic infection or recurrent infection, or there is active skin or soft tissue infection, including cellulitis, erysipelas, pustules, abscesses or fasciitis;
  19. Patients with history of inflammatory bowel disease and / or active bowel disease;
  20. People with uncontrollable pain;
  21. It is known that there is of central nervous system or meninges;
  22. Patients with uncontrollable pleural effusion, peritoneal effusion or pericardial effusion that need clinical intervention, such as those who need periodic repeated drainage or who have had serous effusion drainage recently (within 28 days before the first application);
  23. Patients with uncontrollable chronic systemic diseases (such as severe chronic lung, liver, kidney or heart diseases); patients with arrhythmia, myocardial ischemia and long-term drug control; patients with acute myocardial infarction and current congestive heart failure in the previous year; patients with unstable angina or new angina within the last three months;
  24. Hypertension patients whose systolic blood pressure is less than or equal to 160mhg and diastolic blood pressure is less than or equal to 100mhg;
  25. Patients with known hereditary or acquired bleeding and thrombotic tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism of spleen function, etc.); patients with bleeding tendency or undergoing thrombolysis or anticoagulation treatment; patients with significant clinical bleeding symptoms or clear bleeding tendency within 3 months before screening, such as daily cough/hemoptysis 2.5ml And above, gastrointestinal bleeding, esophageal and gastric varices with bleeding risk, and hemorrhagic gastric ulcer;
  26. Those who have had the event of arteriovenous thrombosis within 6 months after the first use of the study drug, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc;
  27. The subjects or their partners are or intend to be pregnant, and the subjects are or intend to breastfeed are not eligible for inclusion;
  28. Those who have a clear history of neurological or mental disorders (such as depression); those whose objective conditions (including psychological state, family relationship, factors or geographical factors, etc.) make the subjects unable to complete the planned study or other factors that may lead to the forced termination of the study, and those who have combined treatment or laboratory examination abnormalities; 6 Who has a history of alcohol or drug abuse or has any uncontrolled medical condition within six months;
  29. According to the judgment of the researchers, there are serious hazards to the safety of the subjects, or the accompanying diseases (such as severe diabetes) that affect the subjects to complete the study;
  30. The researcher judged that other subjects did not conform to the enrollment of this experiment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SHR-1210 + AIN457

    SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks

    Drug: SHR-1210 · Drug: AIN 457

Interventions

06

What researchers measure

Primary outcomes

  1. DLT (phase Ib)

    Dose Limiting Toxicity

    Time frame: Within four weeks after dosing

  2. Incidence of Treatment-Emergent Adverse Events

    adverse events/serious adverse events

    Time frame: from the first drug administration to within 90 days for the last SHR-1210 and AIN 457 dose

Secondary outcomes

  1. ORR

    Overall Response Rate

    Time frame: From the first drug administration up to two years

  2. BOR

    Best Overall Response

    Time frame: From the first drug administration up to two years

  3. DOR

    Duration of Response

    Time frame: From the first drug administration up to two years

  4. DCR

    Disease Control Rate

    Time frame: From the first drug administration up to two years

  5. PFS

    Progression Free Survival

    Time frame: From the first drug administration up to two years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2020; primary completion for Feb 2022, 23 months later.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 23 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2020
First posted
Mar 6, 2020
StartEst.
Mar 15, 2020
Primary completionEst.
Feb 28, 2022
CompletionEst.
Feb 28, 2023
Last update
Mar 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04298320
Lead sponsor
Yanqiao Zhang
Responsible party
Yanqiao Zhang (Director of the hospital, Harbin Medical University) — Sponsor-investigator
First posted
Mar 6, 2020
Start date
Mar 15, 2020 (estimated)
Primary completion
Feb 28, 2022 (estimated)
Completion
Feb 28, 2023 (estimated)
Last update
Mar 16, 2020

Study contacts

Yanqiao Zhang, PhD
Contact
yanqiaozhang@126.com
+86 138 4512 0210
Yanqiao Zhang, PhD
principal investigator · Harbin Medical University Cancer Hosptital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion